ClinicalTrials.gg

Program

actinium AC-225 dotatate

Also written as “RYZ101”, “RYZ101 Dose Level 1” and “RYZ101 Dose Level 2”.

Its studies are mostly in Breast Neoplasms · Gastro-enteropancreatic neuroendocrine tumor, led by Bristol-Myers Squibb.

Furthest: phase 3, since Jul 20, 20223 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb33 open or runningphase 3since Jul 20, 2022Jul 20, 2022Dec 2026phase 3 · NCT05477576
  • Named in Bristol-Myers Squibb’s own pipeline as RYZ101, phase 3, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 20, 2022First study: phase 3 study in Gastro-enteropancreatic neuroendocrine tumorFirst studyNCT05477576 · 343 enrolled · United States, Belgium, Brazil and more
  2. Sep 16, 2022Phase 1 study in SCLC,Extensive StageNCT05595460 · 21 enrolled · United States, Puerto Rico
  3. Sep 3, 2024Phase 2 study in Breast NeoplasmsNCT06590857 · 64 planned · United States, Canada, South Korea

Ahead

  1. Dec 2026Primary completion: phase 3 study in Gastro-enteropancreatic neuroendocrine tumorNCT05477576
  2. Jul 2027Primary completion: phase 1 study in SCLC,Extensive StageNCT05595460
  3. Oct 2028Primary completion: phase 2 study in Breast NeoplasmsNCT06590857

TargetBeta

“A radioconjugate consisting of the somatostatin analog tyrosine-3-octreotate (Tyr3-octreotate or TATE) labeled, via the macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid (DOTA), with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic…”NCIt, read by Claude

Other programs on SSTR2

ProgramCompanyFurthest phaseStudies
OctreotideruleNovartisphase 436
PaltusotineruleVertex Pharmaceuticalsphase 39
SSTR2-targeting Non-peptide Drug Conjugate CRN09682ruleVertex Pharmaceuticalsphase 21
Actinium Ac 225 SSTR2-targeted Agent RYZ401Bristol-Myers Squibbphase 11
NTQ6179Sino Biopharmaceuticalphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06590857Breast Neoplasms · United States, Canada, South Korea2RecruitingOct 202864
NCT05595460SCLC,Extensive Stage · United States, Puerto Rico1Active, not recruitingJul 202721
NCT05477576Gastro-enteropancreatic neuroendocrine tumor · United States, Belgium, Brazil and more3Active, not recruitingDec 2026343

How it is read

Names in the registry

  • “RYZ101”, 2 entries
  • “RYZ101 Dose Level 1”, 1 entry
  • “RYZ101 Dose Level 2”, 1 entry
  • “RYZ101 Dose Level 3”, 1 entry
  • “RYZ101 Dose Level -1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.